Indeed, a Syk inhibitor (fostamatinib) is approved by the USFDA to be used for anti-inflammation in chronic immune thrombocytopenia [36] and possibly other autoimmune diseases (such as rheumatoid arthritis) along with post-COVID-19 pneumonia [37, 38]. Here, SYK is linked to rheumatoid arthritis.